AXS-05

DRUG10 trials

Conditions

AgitationAgitation in Patients With Dementia of the Alzheimer's TypeAgitation,PsychomotorAlzheimer DiseaseDepressionMajor Depressive DisorderNicotine DependenceSmoking Cessation

Phase 2

Addressing Dementia Via Agitation-Centered Evaluation

CompletedNCT03226522

Axsome Therapeutics, Inc.Agitation in Patients With Dementia of the Alzheimer's Type, Agitation,Psychomotor, Alzheimer Disease

Start: 2017-07-13End: 2020-04-17Updated: 2023-09-13

AXS-05 Phase II Trial on Smoking Behavior

CompletedNCT03471767

James DavisNicotine Dependence, Smoking Cessation, Smoking, Cigarette

Start: 2018-03-25End: 2019-03-31Updated: 2022-12-19

Assessing Symptomatic Clinical Episodes in Depression

CompletedNCT03595579

Axsome Therapeutics, Inc.Major Depressive Disorder

Start: 2018-05-30End: 2019-01-07Updated: 2021-09-24

Mechanistic Evaluation of Response in TRD (MERIT)

CompletedNCT04608396

Axsome Therapeutics, Inc.Major Depressive Disorder, Treatment Resistant Depression

Start: 2020-08-13End: 2021-07-30Updated: 2022-07-12

An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients

NCT04971291

Axsome Therapeutics, Inc.Major Depressive Disorder, Treatment Resistant Depression

Start: 2021-04-14End: 2021-07-31Target: 312Updated: 2021-07-26

Phase 3

A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder

CompletedNCT02741791

Axsome Therapeutics, Inc.Treatment Resistant Major Depressive Disorder

Start: 2016-03-31End: 2020-03-20Updated: 2021-03-24

A Trial of AXS-05 in Patients With Major Depressive Disorder

CompletedNCT04019704

Axsome Therapeutics, Inc.Depression, Major Depressive Disorder

Start: 2019-06-20End: 2019-12-05Updated: 2022-10-12

Assessing Clinical Outcomes in Alzheimer's Disease Agitation

CompletedNCT04797715

Axsome Therapeutics, Inc.Agitation in Patients With Dementia of the Alzheimer's Type, Agitation,Psychomotor, Alzheimer Disease

Start: 2020-12-31End: 2022-11-21Updated: 2023-11-29

A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation

CompletedNCT05557409

Axsome Therapeutics, Inc.Agitation, Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease

Start: 2022-09-06End: 2024-12-21Updated: 2026-08-13

Phase 4

A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

RecruitingNCT06223880

Axsome Therapeutics, Inc.Major Depressive Disorder

Start: 2023-12-27End: 2026-03-31Target: 350Updated: 2025-01-23

Related Papers

Clinical Profile of AXS‐05 in Treating Alzheimer’s Disease Agitation: Results from the Phase 2/3 Development Program

Alzheimer s & Dementia2024-12-01

Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder